Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01860794
Recruitment Status : Recruiting
First Posted : May 23, 2013
Last Update Posted : October 17, 2017
Sponsor:
Information provided by (Responsible Party):
Sang Sup Chung, Bundang CHA Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of clinical trials is to evaluate safety and tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells as a treatment for Patients with Parkinson's disease.

Condition or disease Intervention/treatment Phase
Idiopathic Parkinson Disease Primary Parkinsonism Drug: Mesencephalic Neuronal Precursor Cells Phase 1 Phase 2

Detailed Description:

This study is phase I/II clinical trials which is accessible to those involved in the study and conducted by only Bundang CHA hospital.

The progress of the clinical trails is reported to and evaluated by Data monitoring committee before the enrolment of next human subject.


Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease
Study Start Date : May 2013
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Mesencephalic Neuronal Precursor Cells Drug: Mesencephalic Neuronal Precursor Cells
All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Presence or absence of cancer foramtion and infection [ Time Frame: 5 years ]

    If not included in the following criteria, the cells are are considered to be safe and tolerable.

    • Cells with grade 3 or more in NCI grading system
    • Cells contaminated with infectious materials
    • Cells with risk of cancer formation


Secondary Outcome Measures :
  1. Score of Unified Parkinson's Disease Rating Scale (UPDRS) [ Time Frame: 5 years ]

    UPDRS, most commonly used, is designed to assess the severity of parkinson's disease, making the quantitative measurement of the extent. Part III of UPDRS corresponds to motor evaluation and is the most reliable for detecting symptomatic progression.

    UPDRS improvement ratio(%) = ((the value of UPDRS before surgery - the value of UPDRS after surgery) / (the value of UPDRS before surgery)) X 100


  2. Detection of positron emission in Putamen using Positron emission tomograph(PET) [ Time Frame: 5 years ]
    In pet analysis, putamen activity is investigated via radioactivity before cell transplantation and 12,24,36,48,60 months after the treatment.

  3. Dyskinesia scale scores(CAPSIT-PD) [ Time Frame: 5 years ]
    Overall inspection was carried out before transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, 60 months after the treatment for determining whether the cells have therapeutic effects.

  4. Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test [ Time Frame: 5 years ]
    Comprehensive clinical assessment for examining the improvements in self reporting and timed testing before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment:Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test.

  5. Score of activity of daily living (ADL) scale [ Time Frame: 5 years ]
    Comprehensive clinical assessment for examining the improvements in activity of daily living before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.

  6. Score of Korean mini-mental examination (K-MMSE) [ Time Frame: 5 years ]
    Comprehensive clinical assessment for examining the improvements in mental state before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.

  7. Motor fluctuation scale scores [ Time Frame: 5 years ]
    Comprehensive clinical assessment for identifying the presence of motor fluctuation symptoms before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.

  8. Satisfaction score with patient questionnaire [ Time Frame: 5 years ]
    Measure of patient satisfaction before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.

  9. Dopaminergic drug dose [ Time Frame: 5 years ]
    Measure of dopaminergic drug dose before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.

  10. Tremor, postural instability, motor dysfunction, gait disturbance [ Time Frame: 5 years ]
    Using video recording, assessment for symptoms such as tremor, postural instability, motor dysfunction and gait disturbance before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.

  11. Assessing the extent of recovery with patient's diary [ Time Frame: 5 years ]
    Assessing the extent of recovery based on patient's diary before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Female patients with idiopathic or primary Parkinson's disease
  2. Hoehn and Yare (HY) stage III or IV
  3. more than 33% improvement Part III UPDRS score after one injection of levodopa in the morning
  4. Patients aged less than 70
  5. Great decrease of dopamine uptake in putamen, particularly posterior part, in Positron emission tomograph(PET) before surgery

Exclusion Criteria:

  1. Atypical or secondary parkinsonism
  2. Medical history of severe depression with Beck Depression Inventory(BDI) scores greater than 30
  3. Psychological disorders (illusion, delusion, schizophrenia)
  4. Dementia with K-MMSE(Korean mini-mental state examination) scores less than 24
  5. Epilepsy
  6. Medial history of brain surgery
  7. Medical history of other brain diseases
  8. Hemorrhagic tendency
  9. Severe internal diseases such as poor general condition, hypertension, chronic respiratory disease, ischemic heart disease, cancer
  10. Experience of participating in clinical trial within 30 days
  11. Female patients who have the chances of getting pregnant during clinical trial and do not use the approved birth controls
  12. Pregnant or lactating women
  13. Patients who are not considered to be eligible to participate in clinical trial
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01860794


Contacts
Layout table for location contacts
Contact: Sang Sup Chung, M.D., Ph.D. 82-31-780-5261 jmoon@cha.ac.kr
Contact: Joo pyung Kim, M.D., Ph.D. 82-31-780-5000 jpkim@cha.ac.kr

Locations
Layout table for location information
Korea, Republic of
CHA Bundang Medical Center, CHA University Recruiting
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-712
Contact: Sang Sup Chung, M.D., Ph.D.    82-31-780-5261    sschung@cha.ac.kr   
Contact: In Bo Han, M.D., Ph.D.    82-31-780-5688    hanib@cha.ac.kr   
Principal Investigator: Sang Sup Chung, M.D., Ph.D.         
Sub-Investigator: In Bo Han, M.D., Ph.D.         
Sub-Investigator: Joo Pyung Kim, M.D., Ph.D.         
Sub-Investigator: Yong Soo Choi, Ph.D.         
Sub-Investigator: Hyun Sook Kim, M.D., Ph.D.         
Sub-Investigator: Won Chan Kim, M.D., Ph.D.         
Sub-Investigator: Sang Heum Kim, M.D., Ph.D.         
Sub-Investigator: Eun Hye Yoo, M.D., Ph.D.         
Sub-Investigator: Su Jin Jang, M.D., Ph.D.         
Sub-Investigator: Jisook Moon, Ph.D.         
Sponsors and Collaborators
Bundang CHA Hospital
Investigators
Layout table for investigator information
Principal Investigator: Sang Sup Chung, M.D., Ph.D. CHA University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Sang Sup Chung, Professor, Bundang CHA Hospital
ClinicalTrials.gov Identifier: NCT01860794     History of Changes
Other Study ID Numbers: PBC09-074
First Posted: May 23, 2013    Key Record Dates
Last Update Posted: October 17, 2017
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Dopamine
 Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents